Rabia Gurses Ozden - 17 Jun 2024 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role: Chief Medical Officer
Signature: /s/ John Rakow, Attorney-in-Fact
Issuer symbol: ADVM
Transactions as of: 17 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 20 Jun 2024, 16:50:17 UTC
Previous filing: 06 Feb 2024
Next filing: 06 Aug 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADVM	Stock Option (Right to Buy)	Award	$0	+85,000		$0.000000	85,000	17 Jun 2024	Common Stock	85,000	$7.32	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of June 10, 2024 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Content

Twenty-five percent (25%) of the total number of shares subject to the option shall vest and become exercisable on the first anniversary of June 10, 2024 (the "Vesting Commencement Date"), and one-forty-eighth (1/48th) of the total number of shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.